Doximity, Inc. (NYSE:DOCS – Get Free Report) Director Watkin Phoebe Yang sold 1,290 shares of Doximity stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $26.71, for a total transaction of $34,455.90. Following the completion of the sale, the director directly owned 24,744 shares of the company’s stock, valued at approximately $660,912.24. This trade represents a 4.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Doximity Stock Performance
Shares of NYSE DOCS traded down $0.55 during midday trading on Friday, hitting $27.95. 2,672,127 shares of the stock traded hands, compared to its average volume of 4,021,538. The firm has a market capitalization of $4.98 billion, a P/E ratio of 32.89, a PEG ratio of 22.17 and a beta of 1.22. Doximity, Inc. has a one year low of $17.15 and a one year high of $74.33. The firm has a 50-day moving average of $25.04 and a two-hundred day moving average of $23.23.
Doximity (NYSE:DOCS – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.16 by $0.13. The company had revenue of $156.62 million during the quarter. Doximity had a return on equity of 18.06% and a net margin of 25.48%.The business’s revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.36 EPS. Equities analysts forecast that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.
Institutional Trading of Doximity
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the stock. Evercore set a $35.00 price target on shares of Doximity in a research report on Tuesday. Truist Financial raised their price objective on shares of Doximity from $19.00 to $24.00 and gave the stock a “hold” rating in a report on Thursday, August 13th. Wolfe Research upgraded shares of Doximity to an “outperform” rating in a research report on Thursday, August 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 target price on shares of Doximity in a report on Friday, August 7th. Finally, Stifel Nicolaus set a $27.00 price target on shares of Doximity in a research report on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $31.95.
Check Out Our Latest Stock Analysis on DOCS
About Doximity
Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.
The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.
Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.
Further Reading
- Five stocks we like better than Doximity
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
